<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: \\192.168.1.55\edgar\Anbu\Q Holdings\Qholdings 0331 Q1.xfr; Date: 2012/05/16T20:17:04 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-roles="http://fasb.org/us-roles/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:qhoi="http://qholdings.com/20120331">
    <link:schemaRef xlink:href="qhoi-20120331.xsd" xlink:type="simple" />
    <xbrli:context id="From2012-01-01to2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-05-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-05-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2002-03-28to2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2002-03-28</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2002-03-28to2008-12-31_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2002-03-28</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-03-27_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-12-31_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2009-12-31_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2009-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2002-03-28to2008-12-31_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2002-03-28</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-01-01to2010-12-31_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-03-27_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-12-31_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2009-12-31_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2009-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2002-03-28to2008-12-31_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2002-03-28</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2009-01-01to2009-12-31_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2009-01-01</xbrli:startDate>
        <xbrli:endDate>2009-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-01-01to2010-12-31_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-03-27_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-12-31_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2009-12-31_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2009-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2002-03-28to2008-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2002-03-28</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-03-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-03-27_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2009-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2009-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2002-03-28</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2009-01-01to2009-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2009-01-01</xbrli:startDate>
        <xbrli:endDate>2009-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-01-01to2010-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-03-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-03-27_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2009-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2009-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2002-03-28to2008-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2002-03-28</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2009-01-01to2009-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2009-01-01</xbrli:startDate>
        <xbrli:endDate>2009-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-01-01to2010-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-03-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-03-27_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2009-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2009-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2002-03-28to2008-12-31_NotesReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2002-03-28</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_NotesReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-03-27_NotesReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-12-31_NotesReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2009-12-31_NotesReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2009-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_NotesReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_NotesReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_NotesReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2002-03-28to2008-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2002-03-28</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2009-01-01to2009-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2009-01-01</xbrli:startDate>
        <xbrli:endDate>2009-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-01-01to2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-03-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2009-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2009-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001366541</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2012-01-01to2012-03-31">Q Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2012-01-01to2012-03-31">0001366541</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2012-01-01to2012-03-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2012-01-01to2012-03-31">2012-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2012-01-01to2012-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2012-01-01to2012-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2012-01-01to2012-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2012-01-01to2012-03-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2012-01-01to2012-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2012-01-01to2012-03-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2012-01-01to2012-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2012-01-01to2012-03-31">2012</dei:DocumentFiscalYearFocus>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2012-05-16" unitRef="Shares" decimals="INF">24699298</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">2366088</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2741519</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2002-03-27" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">422198</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-03-31" unitRef="USD" decimals="0">189527</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">31468</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">53796</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">2397556</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2795315</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">28278</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">31923</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssets contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">7513</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">7513</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">2433347</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2834751</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">52442</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">77181</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">231554</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">201613</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesPayableCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">15000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">283996</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">293794</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">2472</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2458</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">20192231</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">19972937</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">-18045352</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-17434438</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">2149351</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2540957</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2002-03-27_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2008-12-31_SeriesAPreferredStockMember" unitRef="USD" decimals="0">25</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2009-12-31_SeriesAPreferredStockMember" unitRef="USD" decimals="0">25</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_SeriesAPreferredStockMember" unitRef="USD" decimals="0">25</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2012-03-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2002-03-27_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2008-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">201</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2009-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">201</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">202</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2012-03-31_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2002-03-27_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2008-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">353</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2009-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">353</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">408</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2012-03-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2002-03-27_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2008-12-31_CommonStockMember" unitRef="USD" decimals="0">419</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2009-12-31_CommonStockMember" unitRef="USD" decimals="0">419</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_CommonStockMember" unitRef="USD" decimals="0">419</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_CommonStockMember" unitRef="USD" decimals="0">2458</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-03-31_CommonStockMember" unitRef="USD" decimals="0">2472</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2002-03-27_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">13780328</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2009-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">13823104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">15179109</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">19972937</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-03-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">20192231</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2002-03-27_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2008-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-13214519</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2009-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-13970250</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-14835100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-17434438</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-03-31_RetainedEarningsMember" unitRef="USD" decimals="0">-18045352</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2002-03-27_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2008-12-31_NotesReceivableMember" unitRef="USD" decimals="0">-135302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2009-12-31_NotesReceivableMember" unitRef="USD" decimals="0">-133502</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_NotesReceivableMember" unitRef="USD" decimals="0">-135302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2012-03-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2002-03-27" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2008-12-31" unitRef="USD" decimals="0">431505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2009-12-31" unitRef="USD" decimals="0">-281450</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">209761</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">2433347</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2834751</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">2282</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2282</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-03-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-03-31" unitRef="Shares" decimals="INF">100000000.</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-03-31" unitRef="Shares" decimals="INF">24722632</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">24582632</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-03-31" unitRef="Shares" decimals="INF">24722632</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">24582632</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RevenueFromGrants contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RevenueFromGrants contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RevenueFromGrants contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">605228</us-gaap:RevenueFromGrants>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LicenseAndServicesRevenue contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">4800</us-gaap:LicenseAndServicesRevenue>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">282900</us-gaap:LicenseAndServicesRevenue>
    <us-gaap:Revenues contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">4800</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">888128</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">224207</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">118667</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">9107778</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">385734</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">214036</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">8046881</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">609941</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">332703</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">17154659</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-609941</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">-327903</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">-16266531</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">441</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentIncomeInterest contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">183783</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">2020</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpense contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">2111197</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">606</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">-209</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">148593</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-973</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">-209</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">-1778821</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-610914</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">-328112</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">-18045352</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2002-03-28to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-610914</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">-328112</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">-18045352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-13214519</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2009-01-01to2009-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-755731</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2010-01-01to2010-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-864850</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-01-01to2011-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-2599338</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-03-31_RetainedEarningsMember" unitRef="USD" decimals="0">-610914</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2002-03-28to2008-12-31" unitRef="USD" decimals="0">-13214519</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2009-01-01to2009-12-31" unitRef="USD" decimals="0">-755731</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">-864850</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-2599338</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-01-01to2012-03-31" unitRef="Shares" decimals="INF">24636955</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2011-01-01to2011-03-31" unitRef="Shares" decimals="INF">4193203</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2011-01-01to2011-03-31" unitRef="USDPShares" decimals="INF">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SharesOutstanding contextRef="AsOf2008-12-31_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">250000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2009-12-31_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">250000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2010-12-31_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">250000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2012-03-31_SeriesAPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2008-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">2013819</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2009-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">2013819</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2010-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">2022190</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2012-03-31_SeriesCPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2008-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">3530185</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2009-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">3530185</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2010-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">4083197</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2012-03-31_SeriesBPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2008-12-31_CommonStockMember" unitRef="Shares" decimals="INF">4193203</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2009-12-31_CommonStockMember" unitRef="Shares" decimals="INF">4193203</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2010-12-31_CommonStockMember" unitRef="Shares" decimals="INF">4193203</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">24582632</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2012-03-31_CommonStockMember" unitRef="Shares" decimals="INF">24722632</us-gaap:SharesOutstanding>
    <qhoi:RecapitalizationDueToReverseMerger contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <qhoi:RecapitalizationDueToReverseMerger contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <qhoi:RecapitalizationDueToReverseMerger contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <qhoi:RecapitalizationDueToReverseMerger contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="USD" decimals="0">260</qhoi:RecapitalizationDueToReverseMerger>
    <qhoi:RecapitalizationDueToReverseMerger contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-260</qhoi:RecapitalizationDueToReverseMerger>
    <qhoi:RecapitalizationDueToReverseMerger contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <qhoi:RecapitalizationDueToReverseMerger contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <qhoi:RecapitalizationDueToReverseMerger contextRef="From2002-03-28to2008-12-31" unitRef="USD" xsi:nil="true" />
    <qhoi:RecapitalizationDueToReverseMergerShares contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="Shares" decimals="INF">2600000</qhoi:RecapitalizationDueToReverseMergerShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="USD" decimals="0">82</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">737</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2002-03-28to2008-12-31" unitRef="USD" decimals="0">819</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="Shares" decimals="INF">818500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="USD" decimals="0">22</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">198</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2002-03-28to2008-12-31" unitRef="USD" decimals="0">220</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="Shares" decimals="INF">219658</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">190000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" decimals="0">25</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">152</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">175</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2010-01-01to2010-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">54</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">383</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2012-01-01to2012-03-31_CommonStockMember" unitRef="USD" decimals="0">19</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7415387</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2010-01-01to2010-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1245954</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3629935</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2012-01-01to2012-03-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">189981</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2002-03-28to2008-12-31" unitRef="USD" decimals="0">7415739</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">1246008</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">3630318</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">1517859</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1750002</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2010-01-01to2010-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">541743</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">3828047</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2012-01-01to2012-03-31_CommonStockMember" unitRef="Shares" decimals="INF">190000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">48</qhoi:ConversionOfNotesPayableIncludingAccruedInterest>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">178</qhoi:ConversionOfNotesPayableIncludingAccruedInterest>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2010-01-01to2010-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">1</qhoi:ConversionOfNotesPayableIncludingAccruedInterest>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5173893</qhoi:ConversionOfNotesPayableIncludingAccruedInterest>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2010-01-01to2010-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">15917</qhoi:ConversionOfNotesPayableIncludingAccruedInterest>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2002-03-28to2008-12-31" unitRef="USD" decimals="0">5174119</qhoi:ConversionOfNotesPayableIncludingAccruedInterest>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterest contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">15918</qhoi:ConversionOfNotesPayableIncludingAccruedInterest>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterestShares contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">482008</qhoi:ConversionOfNotesPayableIncludingAccruedInterestShares>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterestShares contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1780183</qhoi:ConversionOfNotesPayableIncludingAccruedInterestShares>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterestShares contextRef="From2010-01-01to2010-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">6921</qhoi:ConversionOfNotesPayableIncludingAccruedInterestShares>
    <qhoi:ConversionOfNotesPayableIncludingAccruedInterestShares contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2010-01-01to2010-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1395</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2010-01-01to2010-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">836</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2002-03-28to2008-12-31" unitRef="USD" decimals="0">1396</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">837</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">13952</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2010-01-01to2010-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">8371</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="USD" decimals="0">6</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9794</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2002-03-28to2008-12-31" unitRef="USD" decimals="0">9800</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="Shares" decimals="INF">63901</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">940819</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">296444</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2002-03-28to2008-12-31" unitRef="USD" decimals="0">940819</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">296444</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">29308</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">103112</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2009-01-01to2009-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">42776</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2010-01-01to2010-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">83298</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">42378</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2012-01-01to2012-03-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">29308</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2002-03-28to2008-12-31" unitRef="USD" decimals="0">103112</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2009-01-01to2009-12-31" unitRef="USD" decimals="0">42776</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">83298</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">42378</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <qhoi:ExerciseOfOptionsForNotesReceivable contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="USD" decimals="0">49</qhoi:ExerciseOfOptionsForNotesReceivable>
    <qhoi:ExerciseOfOptionsForNotesReceivable contextRef="From2002-03-28to2008-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">135253</qhoi:ExerciseOfOptionsForNotesReceivable>
    <qhoi:ExerciseOfOptionsForNotesReceivable contextRef="From2002-03-28to2008-12-31_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <qhoi:ExerciseOfOptionsForNotesReceivable contextRef="From2002-03-28to2008-12-31_NotesReceivableMember" unitRef="USD" decimals="0">-135302</qhoi:ExerciseOfOptionsForNotesReceivable>
    <qhoi:ExerciseOfOptionsForNotesReceivable contextRef="From2002-03-28to2008-12-31" unitRef="USD" xsi:nil="true" />
    <qhoi:ExerciseOfOptionsForNotesReceivableShares contextRef="From2002-03-28to2008-12-31_CommonStockMember" unitRef="Shares" decimals="INF">491144</qhoi:ExerciseOfOptionsForNotesReceivableShares>
    <qhoi:SubscriptionReceivableShares contextRef="From2010-01-01to2010-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">4348</qhoi:SubscriptionReceivableShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2010-01-01to2010-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">10000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2011-01-01to2011-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">2</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">44748</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">44750</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2011-01-01to2011-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">19457</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger contextRef="From2011-01-01to2011-12-31_SeriesAPreferredStockMember" unitRef="USD" decimals="0">-25</qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger>
    <qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger contextRef="From2011-01-01to2011-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">-202</qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger>
    <qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger contextRef="From2011-01-01to2011-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">-410</qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger>
    <qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">1379</qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger>
    <qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-742</qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMerger>
    <qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMergerShares contextRef="From2011-01-01to2011-12-31_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">-250000</qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMergerShares>
    <qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMergerShares contextRef="From2011-01-01to2011-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">-2022190</qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMergerShares>
    <qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMergerShares contextRef="From2011-01-01to2011-12-31_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">-4102654</qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMergerShares>
    <qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMergerShares contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">13791231</qhoi:ConversionOfPreferredStockToCommomStockInConjunctionWithRevereseMergerShares>
    <qhoi:ConversionOfBridgeNotesToCommonStockInConjunctionWithReverseMerger contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">92</qhoi:ConversionOfBridgeNotesToCommonStockInConjunctionWithReverseMerger>
    <qhoi:ConversionOfBridgeNotesToCommonStockInConjunctionWithReverseMerger contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">916552</qhoi:ConversionOfBridgeNotesToCommonStockInConjunctionWithReverseMerger>
    <qhoi:ConversionOfBridgeNotesToCommonStockInConjunctionWithReverseMerger contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">916644</qhoi:ConversionOfBridgeNotesToCommonStockInConjunctionWithReverseMerger>
    <qhoi:ConversionOfBridgeNotesToCommonStockInConjunctionWithReverseMergerShares contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">916644</qhoi:ConversionOfBridgeNotesToCommonStockInConjunctionWithReverseMergerShares>
    <qhoi:ExchangeOfQTherapeuticsInc.CommonStockForQHoldingsInc.CommonStockInConjunctionWithReverseMerger contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">185</qhoi:ExchangeOfQTherapeuticsInc.CommonStockForQHoldingsInc.CommonStockInConjunctionWithReverseMerger>
    <qhoi:ExchangeOfQTherapeuticsInc.CommonStockForQHoldingsInc.CommonStockInConjunctionWithReverseMerger contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-135487</qhoi:ExchangeOfQTherapeuticsInc.CommonStockForQHoldingsInc.CommonStockInConjunctionWithReverseMerger>
    <qhoi:ExchangeOfQTherapeuticsInc.CommonStockForQHoldingsInc.CommonStockInConjunctionWithReverseMerger contextRef="From2011-01-01to2011-12-31_NotesReceivableMember" unitRef="USD" decimals="0">135302</qhoi:ExchangeOfQTherapeuticsInc.CommonStockForQHoldingsInc.CommonStockInConjunctionWithReverseMerger>
    <qhoi:ExchangeOfQTherapeuticsInc.CommonStockForQHoldingsInc.CommonStockInConjunctionWithReverseMergerShares contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">1853507</qhoi:ExchangeOfQTherapeuticsInc.CommonStockForQHoldingsInc.CommonStockInConjunctionWithReverseMergerShares>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="From2012-01-01to2012-03-31_CommonStockMember" unitRef="USD" decimals="0">-5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="From2012-01-01to2012-03-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="From2012-01-01to2012-03-31_CommonStockMember" unitRef="Shares" decimals="INF">-50000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <qhoi:IssuanceOfStockPricePerShare contextRef="From2002-03-28to2008-12-31_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">1.20</qhoi:IssuanceOfStockPricePerShare>
    <qhoi:IssuanceOfStockPricePerShare contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USDPShares" decimals="INF">2.24</qhoi:IssuanceOfStockPricePerShare>
    <qhoi:IssuanceOfStockPricePerShare contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">2.30</qhoi:IssuanceOfStockPricePerShare>
    <qhoi:IssuanceOfStockPricePerShare contextRef="From2009-01-01to2009-12-31_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">2.30</qhoi:IssuanceOfStockPricePerShare>
    <qhoi:IssuanceOfStockPricePerShare contextRef="From2010-01-01to2010-12-31_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">2.30</qhoi:IssuanceOfStockPricePerShare>
    <qhoi:IssuanceOfStockPricePerShare contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USDPShares" decimals="INF">1.00</qhoi:IssuanceOfStockPricePerShare>
    <qhoi:IssuanceOfStockPricePerShare contextRef="From2012-01-01to2012-03-31_CommonStockMember" unitRef="USDPShares" decimals="INF">1.00</qhoi:IssuanceOfStockPricePerShare>
    <qhoi:StockIssuanceCosts contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">178827</qhoi:StockIssuanceCosts>
    <qhoi:StockIssuanceCosts contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">130441</qhoi:StockIssuanceCosts>
    <qhoi:StockIssuanceCosts contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">197729</qhoi:StockIssuanceCosts>
    <qhoi:AccruedInterestDebtInstrument contextRef="From2002-03-28to2008-12-31_SeriesCPreferredStockMember" unitRef="USD" decimals="0">29692</qhoi:AccruedInterestDebtInstrument>
    <qhoi:AccruedInterestDebtInstrument contextRef="From2002-03-28to2008-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">369427</qhoi:AccruedInterestDebtInstrument>
    <qhoi:AccruedInterestDebtInstrument contextRef="From2010-01-01to2010-12-31_SeriesBPreferredStockMember" unitRef="USD" decimals="0">918</qhoi:AccruedInterestDebtInstrument>
    <us-gaap:DepreciationAndAmortization contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">4968</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">9649</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">378593</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">450000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AccretionExpenseIncludingAssetRetirementObligations contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccretionExpenseIncludingAssetRetirementObligations contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccretionExpenseIncludingAssetRetirementObligations contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">1237263</us-gaap:AccretionExpenseIncludingAssetRetirementObligations>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">29308</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">7330</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">300872</us-gaap:ShareBasedCompensation>
    <qhoi:ResearchandDevelopmentandProfessionalExpenses contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <qhoi:ResearchandDevelopmentandProfessionalExpenses contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <qhoi:ResearchandDevelopmentandProfessionalExpenses contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">44750</qhoi:ResearchandDevelopmentandProfessionalExpenses>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">90000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:AllowanceForLoanAndLeaseLossesRecoveriesOfBadDebts contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllowanceForLoanAndLeaseLossesRecoveriesOfBadDebts contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllowanceForLoanAndLeaseLossesRecoveriesOfBadDebts contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">16813</us-gaap:AllowanceForLoanAndLeaseLossesRecoveriesOfBadDebts>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">22328</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">80322</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">-38281</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">-7513</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-24739</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">-4236</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">52442</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">29941</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">8002</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">648235</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-549108</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">-227045</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">-14872178</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">1323</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">5626</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">406651</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-1323</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">-5626</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">-406651</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromNotesPayable contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromNotesPayable contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">5240000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">15000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">90000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">8661747</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">190000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">3821137</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromStockPlans contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromStockPlans contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">9800</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">2233</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">175000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">17644917</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-375431</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2011-01-01to2011-03-31" unitRef="USD" decimals="0">-232671</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">2366088</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:InterestPaid contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">2020</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2011-01-01to2011-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaid contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">7454</us-gaap:InterestPaid>
    <us-gaap:StockIssued1 contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">220</us-gaap:StockIssued1>
    <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">1079691</us-gaap:DebtConversionOriginalDebtAmount1>
    <qhoi:DebtConversionOriginalDebtAmount2 contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">4110346</qhoi:DebtConversionOriginalDebtAmount2>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2012-01-01to2012-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 12%; font: 10pt/115% Times New Roman, Times, Serif"&gt;&lt;b&gt;1.&lt;/b&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 88%; font: bold 10pt/115% Times New Roman, Times, Serif"&gt;Organization and Summary of Significant Accounting Policies&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Q Holdings, Inc. (the Company) (formerly known&#13;as Grace 2, Inc.) was incorporated on October 27, 2005 as a Delaware corporation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 13, 2011, Grace 2, Inc. entered&#13;into an Agreement and Plan of Merger (Agreement) with Q Acquisition, Inc., a Delaware corporation and wholly owned subsidiary of&#13;the Company (Merger Sub), and Q Therapeutics, Inc. Q Therapeutics, Inc. was incorporated on March 28, 2002 as a Delaware corporation.&#13;Pursuant to the Agreement, Merger Sub merged with and into Q Therapeutics, Inc. with Q Therapeutics, Inc. being the surviving corporation.&#13;Upon the consummation of the merger, the Company acquired 100% of Q Therapeutics, Inc. by issuing 2.1633835 shares of common stock&#13;for each outstanding equity instrument of Q Therapeutics, Inc. After the effective date of the transaction, the former Q Therapeutics,&#13;Inc. stockholders owned 89.7% of the issued and outstanding common shares of Grace 2, Inc. Also, at the time of the transaction&#13;Grace 2, Inc. was renamed Q Holdings, Inc. The transaction was accounted for as a reverse acquisition with Q Therapeutics, Inc.&#13;as the accounting acquirer. The condensed consolidated financial statements include the activity of Q Therapeutics, Inc. from inception&#13;(March 28, 2002) through March 31, 2012, and the activity of Q Holdings, Inc. and Q Therapeutics, Inc. from the date of acquisition&#13;(October 13, 2011) forward.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is a development stage company&#13;in the process of developing products to treat debilitating and fatal diseases of the central nervous system.&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated&#13;financial statements include the accounts of Q Holdings, Inc. and its wholly owned subsidiary, Q Therapeutics, Inc. and Q Therapeutics,&#13;Inc.&amp;#146;s majority owned subsidiary, NeuroQ Research, Inc. (collectively, the Company). All significant intercompany amounts&#13;have been eliminated. There has been no activity in NeuroQ Research, Inc. since NeuroQ Research, Inc. was formed; therefore, no&#13;non-controlling interest is presented. The unaudited condensed consolidated financial statements have been prepared by the Company&#13;pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on a basis consistent with the Company&amp;#146;s&#13;annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments,&#13;necessary to present fairly the financial information set forth therein. Certain information and note disclosures normally included&#13;in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted&#13;pursuant to SEC&lt;b&gt; &lt;/b&gt;rules and regulations, although the Company believes that the following disclosures, when read in conjunction&#13;with the annual financial statements and the notes thereto, are adequate to make the information presented not misleading. Operating&#13;results for the three months ended March 31, 2012, are not necessarily indicative of the results that may be expected for the year&#13;ending December 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Development Stage and Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the period from March 28, 2002 (date of&#13;inception) through March 31, 2012, the Company has not generated significant revenues and has been developing its products. Therefore,&#13;the Company is considered to be in the development stage in accordance with the provisions of Accounting Standards Codification&#13;(ASC) Topic 915, &lt;i&gt;Development Stage Entities&lt;/i&gt;. As required by ASC Topic 915, cumulative amounts have been presented for the&#13;period from March 28, 2002 (date of inception) through March 31, 2012.&lt;b&gt; &lt;/b&gt;Historically, the Company has been dependent on government&#13;grants and debt and equity raised from individual investors to sustain its operations. The Company&amp;#146;s products have not been&#13;approved by the U.S. Food and Drug Administration for commercial sale; therefore, the Company has not generated revenues from commercial&#13;product sales. The Company has incurred losses and used cash in operating activities since inception. As of March 31, 2012, the&#13;Company had an accumulated deficit of $18,045,352. From October 13, 2011 through March 31, 2012, the Company raised $4,018,047&#13;in a private placement of the Company&amp;#146;s common stock. Although there can be no assurance, management believes that the Company&#13;has sufficient resources to fund the Company&amp;#146;s operations through at least March 31, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in&#13;conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect&#13;reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key estimates include useful lives&#13;for property and equipment, valuation allowances for net deferred income tax assets, and values of stock-based compensation awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains its cash in bank deposit&#13;accounts which, at times, exceed federally insured limits. To date, the Company has not experienced a loss or lack of access to&#13;its invested cash; however, there can be no assurance that access to the Company&amp;#146;s invested cash will not be impacted by&#13;adverse conditions in the financial markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid investments&#13;with original maturities to the Company of three months or less to be cash equivalents. As of March 31, 2012 and 2011, the Company&#13;did not have any cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Grants Receivable &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company periodically applies for research&#13;grants, generally as a sub-recipient to grants funded by government agencies through research universities. The Company records&#13;its grants receivable in accordance with the provisions of the grant agreement. The Company&amp;#146;s grants receivable are considered&#13;past due when payment has not been received within 30 days of the invoice date. The amounts of the specific reserves are estimated&#13;by management based on various assumptions including the age of the individual grant receivable, as well as changes in payment&#13;schedules and histories. Grants receivable balances are charged off against the allowance for doubtful accounts when the potential&#13;for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company calculates the estimated fair value&#13;of its stock options and warrants on the grant date using the Black-Scholes option-pricing model and recognizes the estimated fair&#13;value as compensation expense on a straight-line basis over the vesting period. The volatility assumption used in the Black-Scholes&#13;option-pricing model is based on the volatility of publicly traded companies in the same industry as the Company. The expected&#13;term of the options and warrants granted represent the period of time that the options granted are expected to be outstanding.&#13;The risk free rate for periods within the contractual life of the option and warrant is based on the U.S. treasury securities constant&#13;maturity rate that corresponds to the expected term in effect at the time of grant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net income or loss per common&#13;share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding.&#13;Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the&#13;weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding.&#13;Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and&#13;warrants to acquire common stock. Due to the fact that for all periods presented, the Company has incurred net losses,&#13;potential dilutive common share equivalents of 15,707,202 and 8,302,981 for the three months ended March 31, 2012 and 2011,&#13;respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic loss per&#13;common share is the same as diluted loss per common share for the three months ended March 31, 2012 and 2011.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2012-01-01to2012-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: bold 10pt/115% Times New Roman, Times, Serif"&gt;2.&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt/115% Times New Roman, Times, Serif"&gt;Stockholders&amp;#146; Equity&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2012, the Company is authorized&#13;to issue 100,000,000 shares of common stock, of which 24,722,632 shares were issued and outstanding. In addition, a sufficient&#13;number of shares of common stock have been reserved for issuance pursuant to the Company&amp;#146;s 2011 Stock Incentive Plan, as&#13;amended, as well as to permit the exercise in full of all outstanding warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;Holders of shares of common stock are entitled to cast&#13;one vote for each share held at all stockholders&amp;#146; meetings for all purposes, including the election of directors. The common&#13;stock does not have cumulative voting rights.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;Between October 13, 2011 and March 31, 2012, the Company&#13;has been conducting a private placement of its securities solely to accredited investors. The offering is being conducted on a&#13;best efforts basis, whereby the Company is offering for sale a minimum of 3,000,000 and a maximum of 6,000,000 Units, each Unit&#13;consisting of one share of common stock, one 7-year common stock purchase warrant exercisable at $1.00 per share, and one 7-year&#13;common stock purchase warrant exercisable at $2.00 per share. Units sold totaled 4,018,047 through March 31, 2012. The Company&#13;has raised an aggregate of $3,820,318 after paying issuance costs of $197,729. The Company expects to close the private placement&#13;by May 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2012, the Company was authorized&#13;to issue 10,000,000 shares of preferred stock; however, no shares of preferred stock were outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Conversion of Preferred Stock to Common&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 13, 2011, the Company completed&#13;a reverse merger with Q Therapeutics, Inc. at which time all Series A-1, A-2, and B preferred shares of Q Therapeutics, Inc. were&#13;converted into common stock of Q Holdings, Inc. with each preferred share converting into 2.1633835 common shares of Q Holdings,&#13;Inc. Along with this conversion to common stock of Q Holdings, Inc., the holders of Q Therapeutics, Inc. preferred stock forfeited&#13;all rights and preferences.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2012-01-01to2012-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 12%; font: bold 10pt/115% Times New Roman, Times, Serif"&gt;3.&lt;/td&gt;&#13;    &lt;td style="width: 88%; font: bold 10pt/115% Times New Roman, Times, Serif"&gt;Stock Options and Warrants&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Q Therapeutics, Inc. stock option plan,&#13;originally approved on April 10, 2002 and subsequently amended (the 2002 Plan), provides for the grant of incentive options, nonqualified&#13;options, and shares of restricted stock. Under the terms of the 2002 Plan, there are 4,586,373 common shares available for grant&#13;to employees, officers, directors and consultants. The Board of Directors determines the terms of each grant. Generally, the options&#13;have a vesting period of 4 years with 25% vesting after the first year of service and monthly thereafter, and have a 10-year contractual&#13;life. Certain stock options have provisions to accelerate vesting upon the occurrence of certain events. The 2002 Plan converted&#13;to a Q Holdings, Inc. plan in connection with the merger as discussed in Note 1. As of October 13, 2011, there were 228,472 common&#13;shares available to be issued under the 2002 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 13, 2011, the 2011 Stock Option&#13;Plan for Q Holdings, Inc. (the 2011 Plan) was adopted, authorizing 1,500,000 common shares available for grant to employees, officers,&#13;directors and consultants. On October 13, 2011, a majority of stockholders approved the 2011 Plan adopted by the Board of Directors&#13;and approved a total of 1,728,472 shares for issuance under the 2011 Plan with the remaining 228,472 shares previously available&#13;under the 2002 Plan made available for issuance under the 2011 Plan. As of March 31, 2012, there were 878,472 shares available&#13;for option grants under the 2011 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock-based compensation for the three months&#13;ended March 31, 2012 and 2011 was $29,308 and $7,330, respectively. As of March 31, 2012, the Company had $337,352 of unrecognized&#13;stock-based compensation expense related to non-vested awards that will be recognized over a weighted-average period of 3.36 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In conjunction with the 2011 reverse merger,&#13;the options to purchase preferred stock in Q Therapeutics, Inc. were exchanged for options to purchase common stock in Q Holdings,&#13;Inc. Each option in Q Therapeutics, Inc. was exchanged for 2.1633835 options in Q Holdings, Inc. with the exercise price adjusted&#13;down by the same factor, and all other terms remained unchanged.&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 100%; font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"&gt;The following sets forth the outstanding common stock options and related activity for the three months ended March 31, 2012:&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="right" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 115%; font-weight: bold; text-align: center"&gt;Number&amp;#160;of &lt;br /&gt; Options&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 115%; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; Average&lt;br /&gt; Exercise &lt;br /&gt; Price&amp;#160;Per&lt;br /&gt; Share&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="width: 55%; line-height: 115%"&gt;Outstanding as of December 31, 2011&lt;/td&gt;&#13;    &lt;td style="width: 3%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; line-height: 115%; text-align: right"&gt;3,156,948&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 18%; line-height: 115%; text-align: right"&gt;0.14&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 12pt; line-height: 115%"&gt;Granted&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;850,000&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="padding-left: 12pt; line-height: 115%"&gt;Exercised&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 12pt; line-height: 115%"&gt;Forfeited&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-left: 12pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-left: 12pt; line-height: 115%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 12pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 12pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 12pt; line-height: 115%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-left: 12pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Outstanding as of March 31, 2012&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%; text-align: right"&gt;4,006,948&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;$&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;0.32&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&lt;br style="clear: both" /&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2012, the aggregate intrinsic&#13;value of all outstanding options was approximately $2,717,000.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; font: 10pt Times New Roman, Times, Serif; border-left-color: #000000; border-left-width: 0px; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: top"&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 100%; text-indent: 0px; text-align: justify"&gt;The following summarizes information about stock options outstanding as of March 31, 2012:&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; border-left-color: #000000; border-left-width: 0px; font-size: 8pt; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; font-weight: bold; text-align: center"&gt;Exercise &lt;br /&gt;Price&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; font-weight: bold; text-align: center"&gt;Number of &lt;br /&gt;Options &lt;br /&gt;Outstanding&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt;Average &lt;br /&gt;Remaining &lt;br /&gt;Contractual &lt;br /&gt;Life (Years)&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt;Average &lt;br /&gt;Exercise &lt;br /&gt;Price&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; font-weight: bold; text-align: center"&gt;Number of &lt;br /&gt;Options &lt;br /&gt;Exercisable&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; font-weight: bold; text-align: center"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: bottom; background-color: rgb(204,255,204)"&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 13%; text-align: right"&gt;0.06 &amp;#150; 0.08&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 13%; text-align: right"&gt;1,043,220&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 13%; text-align: right"&gt;7.28&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 13%; text-align: right"&gt;0.06&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 13%; text-align: right"&gt;1,043,220&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 13%; text-align: right"&gt;0.06&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: bottom; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: bottom; text-align: right"&gt;0.15 &amp;#150; 0.19&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;2,113,728&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;6.96&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;0.17&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;1,923,531&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;0.17&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: bottom; background-color: rgb(204,255,204)"&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;850,000&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: right"&gt;9.76&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 1.5pt solid; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;53,125&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; vertical-align: bottom; background-color: rgb(204,255,204)"&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 2.5pt double; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 2.5pt double; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;4,006,948&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: right"&gt;7.64&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: right"&gt;0.32&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 2.5pt double; border-left-color: #000000; border-left-width: 0px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-bottom: black 2.5pt double; border-left-color: #000000; border-left-width: 0px; text-align: right"&gt;3,019,876&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: right"&gt;0.15&lt;/td&gt;&#13;    &lt;td style="border-right-color: #000000; border-right-width: 0px; border-top-color: #000000; border-top-width: 0px; background-position: 0px 0px; background-repeat: no-repeat; border-left-color: #000000; border-left-width: 0px; padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;td style="line-height: 115%"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of each stock-based compensation award granted during the three months ended March 31, 2012&#13;was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt"&gt;Risk-free interest rate&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt; text-align: right"&gt;2.61 - 3.36%&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 70%; line-height: 115%; font-size: 10pt"&gt;Expected stock price volatility&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 115%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 26%; line-height: 115%; font-size: 10pt; text-align: right"&gt;62.19%&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt"&gt;Expected dividend yield&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt; text-align: right"&gt;0%&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt"&gt;Expected life of options&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt; text-align: right"&gt;5.5 &amp;#150; 6.5 years&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;br clear="all" style="mso-special-character: line-break" /&gt;&#13;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In conjunction with the reverse merger, the&#13;warrants to purchase preferred stock in Q Therapeutics, Inc. were exchanged for warrants to purchase common stock in Q Holdings,&#13;Inc. Each warrant in Q Therapeutics, Inc. was exchanged for 2.1633835 warrants in Q Holdings, Inc. the exercise price was adjusted&#13;down by the same factor, and all other terms remained unchanged. Additional warrants were issued in 2011 related to the bridge&#13;funding and private placement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="line-height: 115%; font-size: 10pt; text-align: justify"&gt;In connection with certain stock offerings and debt issuances, the Company has issued warrants to purchase stock. The following summarizes information about stock warrants as of March 31, 2012, all of which are exercisable:&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%; font-weight: bold"&gt;Warrants&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 115%; font-weight: bold; text-align: center"&gt;Year of &lt;br /&gt; Expiration&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 115%; font-weight: bold; text-align: center"&gt;Number of &lt;br /&gt; Shares&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 115%; font-weight: bold; text-align: center"&gt;Exercise &lt;br /&gt; Price&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="width: 46%; line-height: 115%"&gt;Common stock warrants issued for previously issued Series A2 warrants&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; line-height: 115%; text-align: right"&gt;2015&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; line-height: 115%; text-align: right"&gt;132,797&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; line-height: 115%; text-align: right"&gt;0.046&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Common stock warrants issued for previously issued Series B warrants&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2015&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;823,347&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;1.035&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Common stock warrants issued for previously issued Series B warrants&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2017&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;192,242&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;0.532&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Warrants issued in conjunction with bridge notes (August 31, 2011)&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2018&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;1,816,644&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Warrants issued in conjunction with bridge notes (August 31, 2011)&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2018&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;916,644&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2.00&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="width: 46%; line-height: 115%"&gt;Warrants issued in conjunction with private placement (October 13 and December 30, 2011)&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; line-height: 115%; text-align: right"&gt;2018&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; line-height: 115%; text-align: right"&gt;3,828,047&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; line-height: 115%; text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Warrants issued in conjunction with private placement (October 13 and December 30, 2011)&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2018&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;3,828,047&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2.00&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Warrants issued for fees in conjunction with reverse merger (October 13 and December 30, 2011)&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2018&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;22,750&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;1.20&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Warrants issued in conjunction with private placement (February 2 and March 30, 2012)&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2019&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;190,000&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Warrants issued in conjunction with private placement (February 2 and March 30, 2012)&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2019&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;190,000&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2.00&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%"&gt;Warrants issued for fees in conjunction with private placement (February 2 and March 30, 2012)&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;2019&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%; text-align: right"&gt;19,000&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;1.20&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCFFCC"&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%; text-align: right"&gt;11,959,518&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;br clear="all" style="mso-special-character: line-break" /&gt;&#13;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Each warrant with an exercise price of $1.00&#13;or $2.00 per share may be redeemed by the Company at a price of $0.001 per share in the event (i) the closing sales price of the&#13;Company&amp;#146;s common stock is at least $1.50 for the $1.00 warrants or $3.00 for the $2.00 warrants for ten consecutive trading&#13;days and (ii) there is an effective public registration statement covering the resale of the common stock issuable upon the exercise&#13;of the warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2012-01-01to2012-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 12%; font: bold 10pt/115% Times New Roman, Times, Serif"&gt;4.&lt;/td&gt;&#13;    &lt;td style="width: 88%; font: bold 10pt/115% Times New Roman, Times, Serif"&gt;Commitments and Contingencies&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;License and Royalty Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has entered into an exclusive license&#13;agreement with a university, where the Company has obtained certain intellectual property from the university to commercialize,&#13;produce, manufacture, use and sell the patent rights. The Company is required to pay the university a contractual dollar amount&#13;for each new investigational drug application filed with the Food and Drug Administration (FDA) using the licensed intellectual&#13;property. Should the Company receive cash payments from licensing revenue during human trial research, the Company is required&#13;to pay 10% of all net licensing revenue (but not including payments for product development activities or equity purchases) to&#13;the university up to a certain maximum amount. The Company is also required to pay an amount upon New Drug Application (NDA) approval.&#13;The NDA approval occurs when the FDA has approved all prior drug testing and allows a new drug to go to the market. Once the Company&#13;has an NDA, the Company must pay the university a royalty of 2% of net sales up to a certain dollar amount and 2.5% of net sales&#13;in excess of that amount of human therapeutics and must pay the university a royalty of 5% of net sales on any services. If the&#13;Company sublicenses the intellectual property, then the Company must pay the university in accordance with the provisions of the&#13;agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has a product development agreement&#13;with an entity, whereby the Company has granted the entity a non-exclusive right to certain intellectual property owned by the&#13;Company and the entity has granted to the Company a non-exclusive right to use certain intellectual property owned by the entity&#13;in order to develop new products (Products) to be sold primarily by the Company or its designees to the research market. The Company&#13;has agreed to pay the entity certain amounts for product development in the form of the Company&amp;#146;s common stock. In addition,&#13;the Company has agreed to pay the entity royalty payments of 10% of net sales of the Company to third parties for Products developed&#13;using the entity&amp;#146;s intellectual property. If the Company agrees that the entity can also sell Products to third parties and&#13;if the entity has sales to a third party of Products using the Company&amp;#146;s intellectual property, then the entity will pay&#13;the Company a royalty payment of 10% of net sales. However, if the Products sold by the entity are covered solely by the Company&amp;#146;s&#13;patents and know-how, then a 50-50 financial sharing arrangement between the entity and the Company will apply to such Products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Right of First Negotiation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to an agreement (Agreement) the Company&#13;has irrevocably granted a stockholder with a right of first negotiation to license certain technology of the Company related to&#13;Q-Cells&amp;#174;. The term of the Agreement is for a period of the later of (i) 3-years from the effective date of the Agreement (October&#13;6, 2011) or (ii) 6-months after the date of completion of certain dosing of the technology.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Asset Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 26, 2012, Q Holdings, Inc., Q Therapeutics,&#13;Inc. and NeuroQ Research, Inc. executed an agreement to acquire certain intellectual property and technology. The agreement is&#13;milestone based and, if the milestones are achieved in 2012, it will provide the Company with manufacturing protocols for several&#13;types of neural cells. The Company will issue payment in the form of common stock and warrants as intellectual property and technology&#13;is delivered to the Company in 2012. In April 2012, the Company issued 10,000 units of common stock and warrants as initial payment&#13;for transfer of intellectual property.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 27, 2012, the Company executed an&#13;agreement for outside research study services. The total contract price is $237,400 and the Company is required to make certain&#13;payments under the agreement as research milestones are met. A payment of $23,700 is due upon authorization of the study. The agreement&#13;is expected to conclude in 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases its office and lab facility&#13;under a non-cancelable operating lease. The current lease was renewed effective April 1, 2011 and expires in March 2013. The minimum&#13;future lease payments under this operating lease as of March 31, 2012 is $73,500 due during the year ending December 31, 2012 and&#13;$27,721 due during the year ending December 31, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Lease expense under operating leases was $36,576&#13;and $38,532 for the three months ended March 31, 2012 and 2011, respectively.&lt;b&gt;&lt;i&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2012-01-01to2012-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: bold 10pt/115% Times New Roman, Times, Serif"&gt;5.&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt/115% Times New Roman, Times, Serif"&gt;Related-Party Transactions&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 9, 2010, the Company entered into&#13;an unsecured note payable agreement with a stockholder for $15,000 with an annual interest rate of 6% and a maturity date of December&#13;31, 2010. The note was repaid during the three months ended March 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;Pursuant to an agreement (Agreement) the Company has&#13;irrevocably granted a stockholder with a right of first negotiation to license certain technology of the Company related to Q-Cells&amp;#174;.&#13;The term of the Agreement is for a period of the later of (i) 3-years from the effective date of the Agreement (October 6, 2011)&#13;or (ii) 6-months after the date of completion of dosing of the technology.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <qhoi:StockIssued2 contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">44750</qhoi:StockIssued2>
    <us-gaap:NotesIssued1 contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">360000</us-gaap:NotesIssued1>
    <qhoi:DebtConversionOriginalDebtAmount3 contextRef="From2002-03-28to2012-03-31" unitRef="USD" decimals="0">90000</qhoi:DebtConversionOriginalDebtAmount3>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2002-03-28to2012-03-31" unitRef="Shares" decimals="INF">916644</us-gaap:ConversionOfStockSharesConverted1>
</xbrli:xbrl>
